Organovo Holdings, Inc. stock is down -25.29% since 30 days ago. The next earnings date is Feb 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 11 December’s closed higher than November.
Organovo Holdings, Inc. focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells. The company is developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases.